Blood Cancer United

As part of its Speaking Out video series, CURE spoke with Dr. Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, about the current research in treatments.

As part of its Speaking Out video series, CURE spoke with Dr. Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, who discussed recent treatment advancements and FDA approvals.

As part of its Speaking Out video series, CURE spoke with Nikki Yuill, oncology social worker and director of the Leukemia & Lymphoma Society’s Information Resource Center, about some of the challenges faced by patients.

As part of its Speaking Out video series, CURE spoke with Nikki Yuill, oncology social worker and director of the Leukemia & Lymphoma Society’s Information Resource Center, about some of the challenges faced by patients.

LLS’s Equity in Access Research Program Awards Five New Grants to Researchers Across the U.S. Aiming to Break Down Barriers to Care for Blood Cancer Patients and Survivors

E. Anders Kolb, MD, pediatric hematologist oncologist, joins LLS on May 1, leveraging decades of visionary scientific leadership and personal dedication to the mission to propel the organization forward.

A nutritionist discussed the difference between mainstream diets and oncology nutrition, and how patients with cancer can ensure they’re on the right track to being well-nourished throughout cancer treatment.

An expert discusses the value of Jaypirca’s recent accelerated FDA approval for relapsed/refractory mantle cell lymphoma, as well as where treatment may go next.

Two experts explain what patients need to know about the recent approval of Brukinsa for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

The past 20 years have brought great advances to advocacy groups, helping to improve patients’ quality of life. But more work is needed to raise awareness in underserved groups.

The best advocate for a patient with cancer is someone who knows exactly what they're going through, noted a multiple myeloma survivor.

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

An expert from the Leukemia & Lymphoma Society breaks down the effectiveness of the COVID-19 vaccine in patients with blood cancers on this episode of the “Cancer Horizons” podcast.

A three-time acute lymphoblastic leukemia survivor became a bone marrow transplant nurse and now helps other patients with the same diagnosis.

Patients with blood cancers may respond differently to doses of the COVID-19 vaccines based on the treatment they’re receiving, for example.

LLS Community is an online gathering place for patients, caregivers and healthcare professionals to share experiences and provide support.

Immune suppressing treatments — an essential component of many patients' cancer care — can blunt vaccine immune response.

Patients with relapsed/refractory, pretreated marginal zone lymphoma are now eligible for treatment with Brukinsa.

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

Patients with blood cancers are at a much higher risk of complications if they contract COVID-19, says an expert from the Leukemia & Lymphoma Society (LLS).

Blood shortages during the COVID-19 pandemic have forced cancer centers to get creative to ensure patients with hematologic malignancies are able to get transfusions in a timely manner.

Susan M. O’Brien, M.D., one of the nation’s foremost leukemia experts, discusses the future of frontline therapies and upcoming clinical trials associated with chronic lymphocytic leukemia.